June 19, 2003

SUMMARY OF INTERVIEW

Attendees, Date and Type of Interview

The interview was conducted on October 18, 2007 and attended by Examiner Lei Yao,

Supervisory Patent Examiner Shanon Foley and Applicants' representatives Daniel Hart and

Jerry Hefner.

Identification of Claims Discussed

Independent claim 15 was discussed.

<u>Identification of Prior Art Discussed</u>

No prior art was discussed.

Proposed Amendments

Applicants' representative proposed amending the claims to replace "THAP1" with "SEQ

ID NO: 3" and to replace "30%" with "95%."

Principal Arguments and Other Matters

Applicants' representatives stated that independent claim 15 was described and enabled

by the specification; however, offered to amend the claim in order to overcome the instant

written description and enablement rejections. The Examiners agreed that the amended claim

would be adequately described by the specification but asked Applicants to provide evidence by

way of a declaration that contacting a chemokine with a chemokine-binding domain of SEQ ID

NO: 3 would produce an inhibition of chemokine activity.

Results of Interview

Applicants' representatives agreed to provide a declaration demonstrating the inhibition

of chemokine activity.

-6-